{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2+Maximum+Tolerated+Dose+determined+in+Phase+1&page=13",
    "query": {
      "intervention": "Phase 2 Maximum Tolerated Dose determined in Phase 1",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 507,
    "total_pages": 51,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2+Maximum+Tolerated+Dose+determined+in+Phase+1&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2+Maximum+Tolerated+Dose+determined+in+Phase+1&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T17:22:06.117Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01045421",
      "title": "Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Nonhematological Malignancies",
        "Non-Small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Metastatic Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Gastroesophageal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "MLN8237 (Alisertib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 273,
      "start_date": "2010-02",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2016-08-15",
      "last_synced_at": "2026-10-14T17:22:06.117Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01045421"
    },
    {
      "nct_id": "NCT03446417",
      "title": "A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "ZN-e4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zeno Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2018-04-20",
      "completion_date": "2022-11-15",
      "has_results": false,
      "last_update_posted_date": "2024-01-25",
      "last_synced_at": "2026-10-14T17:22:06.117Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Detroit, Michigan • East Setauket, New York + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "East Setauket",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Gettysburg",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03446417"
    },
    {
      "nct_id": "NCT03205176",
      "title": "AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Solid Tumors",
        "Lymphoma",
        "Ovarian Cancer",
        "Breast Cancer",
        "Pancreatic Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "AZD5153",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 49,
      "start_date": "2017-06-30",
      "completion_date": "2021-04-08",
      "has_results": false,
      "last_update_posted_date": "2021-05-06",
      "last_synced_at": "2026-10-14T17:22:06.117Z",
      "location_count": 3,
      "location_summary": "Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03205176"
    },
    {
      "nct_id": "NCT05230810",
      "title": "Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HER2-positive Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Alpelisib",
          "type": "DRUG"
        },
        {
          "name": "Tucatinib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Criterium, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2022-08-25",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-10-14T17:22:06.117Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Fort Collins, Colorado • New Orleans, Louisiana + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05230810"
    },
    {
      "nct_id": "NCT02779855",
      "title": "Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Ductal Carcinoma",
        "Invasive Breast Carcinoma",
        "Invasive Ductal Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Talimogene laherparepvec",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2017-05-02",
      "completion_date": "2025-08-26",
      "has_results": true,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-10-14T17:22:06.117Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02779855"
    },
    {
      "nct_id": "NCT00005976",
      "title": "Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "pyrazoloacridine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2000-05",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2013-06-03",
      "last_synced_at": "2026-10-14T17:22:06.117Z",
      "location_count": 22,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Cedar Rapids",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005976"
    },
    {
      "nct_id": "NCT04650555",
      "title": "BIO 300 Oral Powder Safety and Pharmacokinetics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Radiation Syndrome"
      ],
      "interventions": [
        {
          "name": "BIO 300 Oral Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Humanetics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 34,
      "start_date": "2020-12-08",
      "completion_date": "2021-07-06",
      "has_results": true,
      "last_update_posted_date": "2024-05-03",
      "last_synced_at": "2026-10-14T17:22:06.117Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04650555"
    },
    {
      "nct_id": "NCT05096715",
      "title": "Atezolizumab+Bevacizumab+SBRT in Unresectable HCC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unresectable Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic body radiation therapy (SBRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-08-23",
      "completion_date": "2032-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-10-14T17:22:06.117Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05096715"
    },
    {
      "nct_id": "NCT01234519",
      "title": "A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "AEZS-108",
          "type": "DRUG"
        },
        {
          "name": "AEZS-108 at MTD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AEterna Zentaris",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2010-11",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2018-03-15",
      "last_synced_at": "2026-10-14T17:22:06.117Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01234519"
    },
    {
      "nct_id": "NCT05123482",
      "title": "A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Biliary Tract Carcinoma",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Squamous Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "AZD8205",
          "type": "DRUG"
        },
        {
          "name": "AZD8205 and AZD2936 (Rilvegostomig)",
          "type": "DRUG"
        },
        {
          "name": "AZD8205 and AZD5305 (saruparib)",
          "type": "DRUG"
        },
        {
          "name": "AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)",
          "type": "DRUG"
        },
        {
          "name": "AZD8205 in combination with AZD9574",
          "type": "DRUG"
        },
        {
          "name": "AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 460,
      "start_date": "2021-10-18",
      "completion_date": "2027-09-29",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-14T17:22:06.117Z",
      "location_count": 14,
      "location_summary": "Duarte, California • Irvine, California • Santa Monica, California + 11 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05123482"
    }
  ]
}